This study addresses the mechanism of transport of the H2-receptor antagonist, cimetidine, by the human placenta. A 4-h recycling perfusion of a single placental cotyledon of normal, term, human placenta was used. At a maternal concentration of 1 ug/ml, cimetidine clearance from the maternal circulation was 0.58±0.16 ml/min per g placenta, a rate about one third that of antipyrine. There was no evidence of cimetidine metabolism by the placenta. Transfer of cimetidine from maternal to fetal compartments showed no saturation kinetics and was not inhibited by putative carrier competitors. Cimetidine did not accumulate against a drug concentration gradient. Fetal clearance of cimetidine was similar to maternal clearance. Studies with placental apical vesicles confirmed lack of saturability of cimetidine transport and of its concentration within vesicles. Thus, (a) cimetidine is transported across the human placenta bidirectionally at a rate about one third that of antipyrine, (b) the drug is not metabolized by the placenta, and (c) the transport is a passive one.
Introduction
The H2-receptor antagonists, of which cimetidine (Tagamet) and ranitidine (Zantac) are best known, are some of the most commonly prescribed therapeutic agents in current clinical use in the United States. These drugs are generally given for the treatment of peptic ulcer disease (1) , but the indications seem to have been broadened recently (2) .
Pregnant women often suffer from heartburn secondary to decreased esophageal tone and motility as well as the upward displacement and compression of the stomach by the uterus. They are also at risk of gastric acid aspiration (Mendelson's syndrome) during delivery under general anesthesia (3) . The former problem is generally treated with antacids and for the latter some have suggested a brief use of cimetidine (3) . Based on the latter experience and studies in animals, it is known that cimetidine can cross the placenta (4) . However, the extent and mechanism of its transfer in humans are uncertain. Prolonged use of cimetidine in pregnancy is currently not sanctioned, except in compelling individual circumstances (5) . In sheep, it has been determined that cimetidine (as well as ranitidine) crosses the placenta, that the binding on either side of the placenta is comparable, that the fetal kidneys excrete the drug and that the placenta apparently controls the rate of cimetidine transfer into the fetal circulation (6) (7) (8) . The mecha-nism(s) of the transfer in sheep were not established, but the possibility of active transport of the drug from the fetal to the maternal circulation was strongly sugggested (8) . The interpretation of these latter studies was hampered by the presence of the fetus in the system, rendering analysis of placental function alone difficult. Furthermore, sheep placenta differs morphologically from human placenta (9) .
The purpose of the present study, therefore, was to assess comprehensively the mechanism(s) of human placental transport of cimetidine. To define the manner in which these drugs are transported by the placenta, we utilized the perfused human placental cotyledon system (10) and maternal-facing (apical) microvilli prepared from human placental syncytiotrophoblast (1 1) .
Methods

Subjects
Placentas from 59 women were used. Of these, all but three were at term, the others were 30, 35, 36 wk. Of the 59 studies all but four were pregnancies without known complications. Three pregnancies were complicated by pregnancy-induced hypertension, one by class A (gestational) diabetes. In most instances, placentas were obtained by vaginal delivery under no anesthesia or only local anesthesia. In a few instances (5), the placenta was delivered by Cesarean section. No apparent difference was noted in studies with either delivery mode or in the four pregnancies with medical disorders. Hence, the data were pooled. The women ranged in age between 15 and 37 yr with a mean age of 22.6±4.4 yr. The (12) (13) (14) (15) has been adopted for local use. Briefly, a normal human term placenta obtained immediately after delivery was used. The tissue was perfused immediately with heparinized cold Krebs-Ringer buffer, the fetal vessels supplying a well-defined cotyledon were cannulated with polyethelene catheter and after ascertaining good flow and lack of leakage via tears, the placenta was mounted in a plexiglass chamber with the maternal surface facing upward. The blanched cotyledon on the maternal side was perfused with two or three properly placed needles placed 2-3 mm below the maternal surface, in the intervillous space. The perfusion fluid consisted of Krebs-Ringer buffer, pH 7.4, containing fetal blood obtained from the cord (hematocrit -20%) and human albumin (Alpha Therapeutic Corp., Los Angeles, CA) at a concentration of 2 g/100 ml. Temperature was maintained at 370C, the pressure in the system was monitored and maintained at 40-60 mmHg, and the pH was maintained at 7.4 by adjustment ofCO2 in the system. The system was usually oxygenated with 21% 02 and 5% CO2-In some studies 95% 02 was employed. These differences in 02 delivery systems had no differential effect on placental viability or function. The fetal flow rate was usually 2-4 ml/min. This rate has been used by others (15) with maintenance ofplacental integrity. The perfusion lasts 2.5-4 h, depending on the approach used, and was successful in our hands in -90% of instances.
Two types of perfusion systems were employed. In one system, the A (12) . Because of its slower rate of transfer, cimetidine clearance in either direction was also defined by the formula: Cl = (K X V)/C, where K = slope ofdrug appearance in the recipient reservoir, V = recipient perfusate volume, and C = mean drug concentration in the donor circuit. Another method involved calculation of cimetidine clearance by determining the drug area under the curve (AUC)' over 4 h in the maternal or fetal circuit and dividing the dose initially placed therein by the AUC. All three methods for cimetidine gave similar results. Clearances were expressed as milliliters per hour per gram of tissue.
Validation ofplacental integrity. Both perfusion systems previously described have been validated in the past for absence of nonspecific leakage, for viability by measurements of oxygen and glucose consumption and a predicted (low) lactate output, as well as by light and electron microscopy (12) (13) (14) (15) (16) . In our studies, also, there was absence of transfer of bromosulphthalein (BSP), a water-soluble dye of 838 mol wt, in either direction. The spectrophotometric assay (17) permits exclusion of all but 2% of BSP transfer from either reservoir. Only 3.12±1.65% of '4C-inulin (mol wt 5,000) crossed the placenta, as reported by others (10, 14) . Maternal placental endogenous chorionic gonadotropin (mol wt 36,700) accumulated in the maternal reservoir but none was detected on the fetal side by radioimmunoassay (18) . There was no leakage of fluid from fetal to maternal reservoirs or in the reverse direction as measured at the end of each study. In our studies, the pressure in the perfusion system consistently remained between 40 and 60 mmHg, glucose consumption was 7.04±0.562 mg/g placenta per h and remained constant throughout the study, and lactate output (combined maternal and fetal) was 1.35±0.559 umol/g placenta per h. This glucose consumption is somewhat higher than that reported by others, and so is the lactate output (10, 15, 19) . In a few studies with low lactate output (-0.5 Amol/g per h), the transport data for cimetidine were similar to those seen with 1.5 urmol lactate/g per h output. When 21% 02 was used, the fetal arterial 02 partial pressure, measured with a 1302 pH/blood gas analyzer (Instrumentation Laboratory, Inc., Lexington, MA), was similar to those of others (14). There was no difference in lactate output, cimetidine transfer, or a-aminoisobutryic acid transport by the placenta with 21 or 95% oxygenations. Hence, 21% 02 was used in most studies, as it permitted easier regulation of perfusate pH. Fetal blood flow in our system varied from 2 to 4 ml/min, similar to that seen in other well-validated studies (15) , but somewhat lower than in reports which generally perfused larger placental lobules (19) . Maternal flow was 20 ml/min.
Specific perfusion experiments. A series of recirculating perfusion experiments were carried out with various concentrations of cimetidine (1-100 Ag/ml placed in the maternal or fetal reservoir) with determination of transfer into the opposite compartment. In these experiments antipyrine was usually added as a well-defined transport marker. Antipyrine had no effect on the rate ofcimetidine transport. In other studies, D-and L-glucose were added to verify the presence of 1. Abbreviations used in this paper: AIB, '4C-a-aminoisobutyric acid; AUC, drug area under the curve; BSP, bromosulphthalein.
Human Placental Transport ofCimetidine 1429 facilitated and passive transport, respectively, and thus validate the function ofthe system. In some experiments, '4C-inulin (mol wt 5,000) was added to the perfusate as another validating marker of known placental transport. In some studies imidazole, a structural ring antagonist of cimetidine, in 10-or 100-fold excess, or ranitidine or quinine (putative organic cation competitors [20, 21] ) in 10-and 100-fold excess, respectively, were added to the maternal perfusion circuit. At the conclusion of each study, the perfused placental lobule and contiguous nonperfused tissue were assayed for cimetidine and antipyrine.
A series of open perfusion studies were also carried out to determine if cimetidine and cycloleucine crossed from the maternal to fetal reservoirs against a concentration gradient, and for optimal comparative cimetidine vs. antipyrine clearances.
Other placental studies Cimetidine metabolism. Metabolism ofcimetidine by the placenta was assessed by assaying for the parent drug and its metabolites in both perfusates and the placenta in the perfusion experiments, as well as by incubating in vitro unlabeled and 3H-labeled cimetidine with human placental microsomes and determining the recovery ofthe parent drug and formation of any metabolites over 60 min. In the perfusion studies, based on the radiolabeled cimetidine added and the sensitivity of the high-performance liquid chromatography (HPLC) system, all but 2-3% ofany cimetidine metabolites present would have been detected.
As a control for the in vitro studies, 4C-caffeine, "4C-aminopyrine, and '4C-antipyrine were also incubated with the same microsomes. Placental microsomes were isolated and assayed for drug metabolism by methods reported by us earlier (22, 23) .
Cimetidine binding in perfusate. < 20% of cimetidine is normally bound by plasma proteins in man (24) . Nevertheless, binding of the various concentrations of drug by the perfusion solution with 2 g albumin/dl vs. that with 4 g albumin/dl was determined to assess whether this could vary enough to influence placental transport of the drug. Binding studies were carried out as described previously by us using equilibrium dialysis (25) .
Vesicle studies. Maternal facing (apical) microvillous membrane vesicles were prepared from human placental syncytiotrophoblast using the method of Smith et al. (1 1 (10, 16) (Fig. 1 and Tables I and II). As shown in Table II , the clearance of cimetidine at this concentration from the maternal circuit was 0.576±0.157 ml/h g placenta. When the clearance of cimetidine from the maternal circuit was studied at varying concentrations (from 1 to 100 ug/ml), the clearance was similar (Table II) . Expression of these data as the antipyrine/cimetidine transfer ratio into the fetal circuit, to correct for interplacental variation in fetal blood flow also showed no differences in transfer of the cimetidine over a 100-fold concentration range in the maternal reservoir. Plotted in a different way, there was an increasing but linear transfer of the cimetidine from maternal to fetal compartments with increasing maternal cimetidine concentrations (r = 0.81251, P < 0.01). These data show absence of saturation kinetics of cimetidine transfer from maternal to fetal compartments and are consistent with passive transport. As is shown in Fig. 2 , when cimetidine was infused at steady state into the maternal compartment and the same concentration of the drug was placed into a recirculating fetal compartment, the drug did not cross the placenta against a concentration gradient, i.e., it did not accumulate in the fetal reservoir. This is not consistent with active transport and differs from the transport of cycloleucine vs. a concentration gradient in two of these studies (Fig. 2) . Cycloleucine is known to be transferred by the placenta by active transport (13) . Similarily, as shown in Fig. 3 , D-glucose (known to be transferred by the placenta by facilitated (carrier-mediated) transport was, in fact, transferred into the fetal reservoir more rapidly than L-glucose, which is known to be transferred passively (16) . Interestingly, in the same studies, cimetidine, with a mol wt of 252.32, similar to that of glucose which is 180, was transferred at a rate very similar to that of L-glucose.
To examine further the possibility that cimetidine may be transferred via the placenta by a carrier-mediated transport, imidazole (the ring-structural analog of cimetidine) was added to the maternal reservoir in 10-fold higher concentration. However, no significant effect on cimetidine transfer was seen when comparing three control with two imidazole studies. In two other studies (not shown) with imidazole in 100-fold excess over a cimetidine concentration of 1 gg/ml, again no inhibitory effect of imidazole was noted. The possibility that ranitidine or quinine (21) competition for an organic cation carrier in the placenta also was not borne out.
In view ofthe studies carried out with sheep placenta (7, 8) , the possibility was considered that fetal to maternal transfer of cimetidine may be greater than in the reverse direction. However, at a concentration of 1.0 ug/ml of the drug in the fetal circuit, clearance was similar (Table I and II) to that seen from the maternal circulation. In 4 h the maternal cimetidine concentration was 0.11 sg/ml, i.e., 37.4% of the fetal dose had been transferred into the maternal reservoir. The similar clearance ofthe drug in both directions implies lack ofany selectiv- ity (preferred direction) of transport. Moreover, varying concentrations of cimetidine, over a 100-fold range, exhibited the same clearance from the fetal circuit. As expected for passive transport, the amount of cimetidine transferred from fetal to maternal circuits correlated linearly (r = 0.8739) with the dose ofthe drug placed in the fetal compartment. However, because An open perfusion system was used on the maternal side and a recirculating one for the fetus (see Methods). 150 mg of cimetidine was placed on the maternal side yielding a steady-state concentration of 50 ,g/ml on that side. The same concentration of cimetidine was placed in the fetal reservoir. Cycloleucine concentrations of 12.9 gg/ml were set up in the maternal circuit (open system) and the same in the fetal (recirculating) reservoir. Data are given as mean±SE of the number of cimetidine studies listed. The study shows accumulation of cycloleucine (n = 2) in the fetal compartment against a concentration gradient (active transport), but the ratio was at -1.0 for cimetidine (passive transport). (Fig. 4) . This lack of saturation of uptake with increasing dose suggests passive transport ofcimetidine. Determinations of extra-and intravesicular concentrations of cimetidine were similar, also consistent with passive transport. Thus, the studies with apical microvillous vesicles corroborate the perfusion studies in describing transport consistent with passive transfer of cimetidine across this portion of the placental membrane.
Discussion
This study clearly demonstrates that cimetidine crosses the human placenta in both directions, maternal to fetal and vice versa. The clearance of the drug in the perfused placental cotyledon model from the maternal to fetal reservoirs is 0.576±0.157 ml/h per g of placenta. Expressed in terms of simultaneous transfer of a readily diffusible substance, antipyrine, the transport rate of cimetidine was about one third that of antipyrine. The clearance of cimetidine from the fetal t 100-* Figure 4 . The mechanism of cimetidine transfer via the human placenta is also elucidated by this study. The transfer had all the characteristics of passive transport. The evidence for this is (a) lack of saturation kinetics over a 100-fold cimetidine dose range in either direction (maternal to fetal and vice versa), (b) no inhibition of transport by a large excess of imidazole, a structural ring analog, or by quinine or ranitidine, likely organic base carrier inhibitors (20, 21) , (c) similar rate of transport as for L-glucose, which has a similar molecular weight but is more polar and has no charge and is known to be transferred passively, and most important, (d) no transfer across the placenta against a drug concentration gradient. By contrast, in some of the same studies, cycloleucine, known to be transferred actively, did accumulate in the fetal compartment against a concentration gradient. Furthermore, in some of these experiments, facilitated (carrier-mediated) transfer of Dglucose and passive transport of L-glucose was demonstrated, indicating that the system was capable of such differential function. Data with apical (maternal-facing) placental vesicles confirm the absence of saturation kinetics (i.e., uptake is linear with increasing concentration), and lack of accumulation of the drug in the vesicles against a concentration gradient. These data are consistent with passive transport. The data also imply lack of binding of the cimetidine to this placental membrane.
It has been suggested from data in sheep that placenta may metabolize cimetidine (7) . No evidence for this was found with human placental microsomes or during placental perfusion with labeled cimetidine over 4 h. Furthermore, binding to plasma proteins is unlikely to exert an important effect on cimetidine transport via the placenta, as binding was very low, only 4 .8%, and it did not vary with a change in albumin concentration from 2 to 4 g/100 ml of buffer.
Two further comments are pertinent. First, because transport of cimetidine by the placenta appears to be passive, the drug is not metabolized by the placenta and plasma binding of cimetidine is minor, at steady state the concentrations of cimetidine in maternal and fetal compartments will be in equilibrium. With short-term or intermittent drug usage, however, fetal cimetidine concentration may depend not only on its rate of transport by the placenta but also on human fetal renal clearance of the drug. In sheep, the fetal renal secretion of cimetidine in absolute terms was low, but adjusted for creatinine clearance, extraction of cimetidine was comparable with that by the adult kidneys (7) . No such data for the human fetus are available. In addition, the present data refer to mature, term placenta. It is uncertain whether transfer of the drug will be altered during human placental maturation, but the placenta is known to decrease in thickness during development (30) and this is one determinant of permeability (31) . Preliminary studies in our unit, however, comparing term and /4 term baboon perfused placenta show no difference in cimetidine transport at these two times. Moreover, the baboon placenta seems to transfer cimetidine at a similar rate as the human placenta (unpublished data). Second, one must consider the possible effects of cimetidine on the fetus. Antiandrogenic effects have been reported for male progeny in pregnant rats given large doses of cimetidine during gestation and lactation (32, 33) . The relevance of this observation to pregnant patients and their offspring is uncertain.
